Certa Therapeutics presents positive data from a Phase 2 cli

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Australia , Melbourne , Victoria , University College , New South Wales , San Diego , California , United States , United Kingdom , London , City Of , Australian , Kirrily Davis , Darren Kelly , Frederickgl Huetwell , Sue Charles , European Medicines Agency , Drug Administration , American College Of Rheumatology , Scleroderma Program , Australian Therapeutic Goods Agency , Linkedin , Centre For Rheumatology , American College Of Rheumatology Combined Response Index , Professor Chris Denton Md University College London , American College Of Rheumatology Annual Meeting , University Of Michigan Ann Arbor , American College , Rheumatology Annual Meeting , Professor Chris Denton , University College London , Rheumatology Combined Response Index , Systemic Sclerosis , Rodnan Skin Score , Joint Director , Royal Free Hospital , Experimental Rheumatology , Orphan Drug Designation , Ann Arbor , Professor Darren Kelly , Presentation Time , Brandon Biocatalyst , Australian Therapeutic Goods , Lacerta Therapeutics ,